# GSK receives EMA validation for Jemperli plus chemotherapy

- Link: https://www.directorstalkinterviews.com/gsk-receives-ema-validation-for-jemperli-plus-chemotherapy/4121116529
- Published: 2023-04-25T07:30:32+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that the European Medicines Agency (EMA) validated 
the Company’s Type II Variation for a potential new indication for _Jemperli_ (dostarlimab)
in combination with chemotherapy for the treatment of adult patients with a type
of gynaecological cancer known as mismatch repair deficient (dMMR)/microsatellite
instability-high (MSI-H) primary advanced or recurrent endometrial cancer. As a 
result, the EMA’s Committee for Medicinal Products for Human Use will begin the 
formal review process to make a recommendation to the European Commission regarding
marketing authorisation for the potential new indication.

The regulatory submission is based on the interim results of the RUBY/ENGOT-EN6/
GOG3031/NSGO phase III trial. The trial met its primary endpoint of investigator-
assessed progression-free survival, showing a statistically significant and clinically
meaningful benefit versus placebo plus chemotherapy in patients treated with dostarlimab
plus carboplatin-paclitaxel in the dMMR/MSI-H population. In addition, the safety
and tolerability profile of dostarlimab in combination with carboplatin-paclitaxel
was generally consistent with the known safety profiles of the individual agents.
The results were presented on 27 March 2023 at a European Society for Medical Oncology
Virtual Plenary and the Society of Gynecologic Oncology Annual Meeting and simultaneously
published in _The New England Journal of Medicine_.

> **Hesham Abdullah, Senior Vice President, Global Head of Oncology Development,
> GSK** said: “New treatment options are urgently needed for patients with primary
> advanced or recurrent endometrial cancer. With this initial filing, we are accelerating
> the submission of a potential new indication for dostarlimab in the patient population
> that demonstrated the strongest treatment effect in the RUBY phase III trial. 
> These patients currently face significant unmet medical needs, and this combination
> could change the treatment paradigm for this condition. The RUBY phase III trial
> continues to follow patients for the dual-primary endpoint of overall survival
> in the intent-to-treat population.”

GSK expects US regulatory filing review based on the RUBY Phase III trial results
to occur in the first half of 2023.

**About endometrial cancer**

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium.
Endometrial cancer is the most common gynaecologic cancer in developed countries,
with approximately 417,000 new cases reported each year worldwide, and incidence
rates are expected to rise by almost 40% by 2040. Approximately 15-20% of patients
with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.

**About RUBY**

RUBY is a two-part global, randomised, double-blind, multicentre phase III trial
of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating
dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-
paclitaxel plus placebo followed by placebo. Part 2 is evaluating dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus
carboplatin-paclitaxel followed by placebo. The primary endpoints in Part 1 are 
investigator-assessed PFS based on the Response Evaluation Criteria in Solid Tumours
v1.1 and OS. The statistical analysis plan included pre-specified analyses of PFS
in the dMMR/MSI-H and ITT populations and OS in the overall population. Pre-specified
exploratory analyses of PFS in the MMRp/MSS population and OS in the dMMR/MSI-H 
populations were also performed. RUBY Part 1 included a broad population, including
histologies often excluded from clinical trials and had approximately 10% of patients
with carcinosarcoma and 20% with serous carcinoma. In Part 2, the primary endpoint
is investigator-assessed PFS. Secondary endpoints in Part 1 and Part 2 include PFS
per blinded independent central review, overall response rate, duration of response,
disease control rate, patient-reported outcomes, and safety and tolerability.

**About _Jemperli_ (dostarlimab)**

_Jemperli_ is a programmed death receptor-1 (PD-1)-blocking antibody that binds 
to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and 
PD-L2.

_Jemperli_ is not approved anywhere in the world for use in combination with standard-
of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab for primary
advanced or recurrent endometrial cancer. In the US, _Jemperli_ is approved for 
adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial
cancer, as determined by a US FDA-approved test, that has progressed on or following
a prior platinum-containing regimen in any setting and are not candidates for curative
surgery or radiation. _Jemperli_ is also indicated in the US for patients with dMMR
recurrent or advanced solid tumours, as determined by a US FDA-approved test, that
have progressed on or following prior treatment and have no satisfactory alternative
treatment options. The latter indication is approved in the US under accelerated
approval based on tumour response rate and durability of response. Continued approval
for this indication in solid tumours may be contingent upon verification and description
of clinical benefit in a confirmatory trial(s).

_Jemperli_ was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under
a collaboration and exclusive license agreement signed in March 2014. The collaboration
has resulted in three monospecific antibody therapies that have progressed into 
the clinic. These are: _Jemperli_ (GSK4057190), a PD-1 antagonist; cobolimab, (GSK4069889),
a TIM-3 antagonist; and GSK4074386, a LAG-3 antagonist. GSK is responsible for the
ongoing research, development, commercialisation, and manufacturing of each of these
medicines under the agreement.

**Important Information for _Jemperli_ in the EU **

**Indication  **

_Jemperli_ is indicated as monotherapy for treating adult patients with mismatch
repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced
endometrial cancer that has progressed on or following prior treatment with a platinum-
containing regimen.  

Refer to the Jemperli EMA Reference Information for a full list of adverse events
and the complete important safety information in the EU. 

Share on:
